Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1618 1674
This examiner grants 0% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18043716 | CHIMERIC RECEPTORS WITH DIVERSE CO-REGULATORY SEQUENCES | Non-Final OA | The Regents of the University of California |
| 18482399 | TREATMENT AND PREVENTION OF METABOLIC DISEASES | Non-Final OA | National University of Singapore |
| 18296755 | EXOSOME ENCODED IL-10 AS A TREATMENT FOR INFLAMMATION ASSOCIATED ADVERSE PREGNANCY CONDITION | Non-Final OA | Board of Regents, The University of Texas System |
| 17778593 | METHOD FOR DETECTING CANCER BONE METASTASIS AND DETECTION REAGENT | Non-Final OA | TOSOH CORPORATION |
| 18199248 | Anti-DFS70 Autoantibodies and methods of attenuating formation of nets | Non-Final OA | McMaster University |
| 18128310 | Method of Treating Psoriasis with IL-23 Specific Antibody | Non-Final OA | Janssen Biotech, Inc. |
| 18327193 | TRAIL COMPOUNDS FOR REDUCING CANCER TREATMENT SIDE EFFECTS | Non-Final OA | BROWN UNIVERSITY |
| 18261368 | TREATMENT OF DRY EYE SYNDROME USING AN OPHTHALMIC COMPOSITION COMPRISING TANFANERCEPT | Non-Final OA | HANALL BIOPHARMA CO., LTD. |
| 18265380 | COMPOSITIONS AND METHODS FOR TREATING OCULAR DISEASES | Non-Final OA | Annexon, Inc. |
| 18140535 | METHOD AND COMPOSITION OF TREATMENT OR PREVENTION OF CORONAVIRUS INFECTION | Non-Final OA | AINOS INC. |
| 18033524 | IL-2/IL-15R-BETA-GAMMA AGONIST FOR TREATING NON-MELANOMA SKIN CANCER | Non-Final OA | Cytune Pharma |
| 18033252 | GRANULOCYTE MACROPHAGE-COLONY STIMULATING FACTOR MUTANTS | Non-Final OA | Partner Therapeutics, Inc. |
| 18297983 | Compositions and Methods for Treating Solid Tumors with Anti-BTLA as Mono or Combination Therapy | Non-Final OA | SHANGHAI JUNSHI BIOSCIENCES CO., LTD. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy